Skip to content

A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure

A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05875649
Acronym
CLAG
Enrollment
137
Registered
2023-05-25
Start date
2023-07-02
Completion date
2027-12-20
Last updated
2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML

Keywords

CLAG, acute myeloid leukemia, First-induction failure

Brief summary

Most of patients with acute myeloid leukemia achieved complete remission (CR) after primary induction chemotherapy, there were 20-30% patients without CR after first-induction. It was uncertain how to treat these patients. It was investigated in our study that these patients were re-induced with CLAG Regimen. The CR ratio, overall survival (OS) and relapsed-free survival (RFS) was statistically analysed in these patients.

Interventions

COMBINATION_PRODUCTCLAG

Acute myeloid leukemia patients are re-induced by CLAG Regimen after first-induction failure

Sponsors

Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Acute myeloid leukemia patients with first-induction failure

Exclusion criteria

* Acute myeloid leukemia patients with serious infection and organ dysfunction.

Design outcomes

Primary

MeasureTime frameDescription
Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction failure6 monthsCLAG Regimen improves CR rate in acute myeloid leukemia patients with first-induction failure

Countries

China

Contacts

Primary ContactXuejie Jiang, Doctor
jxj3331233@163.com+86 18688869522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026